August 30, 2017
Historic moment in cancer treatment for Novartis
US Food and Drug Administration (FDA) has approved Novartis’s Kymriah suspension for intravenous infusion, formerly CTL019, the first chimeric antigen…
Pharmaceuticals, Biotechnology and Life Sciences
Category: news
August 30, 2017
Positive outlook for STADA’s business development in 2017
Stada’s Executive Board presented sound figures for financial year 2016 and a positive outlook for business development in 2017. Board’s…
August 30, 2017
OptiBiotix profit after tax £3.2M
OptiBiotix has made significant progress in the last six months developing a pipeline of innovative products with a strong scientific and clinical evidence base, said Stephen O’Hara, CEO of OptiBiotix Wednesday in the half year financial report.
August 30, 2017
Amryt Pharma names new strategic licensing and licensing VP
Amryt Pharma, a biopharmaceutical company focused on rare and orphan diseases, has appointed Kieran Rooney, as Vice President of Strategic Alliances and Licensing.
August 29, 2017
Allergan settles with Famy Care over patent litigation
Allergan has reached a settlement regarding its litigation with Famy Care Limited relating to certain Allergan’s United States Patent covering Restasis (Cyclosporine Ophthalmic Emulsion) 0.05%.
August 28, 2017
No anti-inflammatory effect with GeNeuro’s/Servier’s multiple sclerosis drug at 6 months
GeNeuro and Servier on Monday said that GNbAC1, for the treatment of certain multiple sclerosis was well tolerated, without statistical…
August 28, 2017
Sanofi buys US-based Protein Sciences
Sanofi has acquired USA based Protein Sciences, a vaccines biotechnology company located in Meriden, Connecticut. The Federal Trade Commission’s approval…
August 28, 2017
China’s CF PharmTech raises $65M in Series D financing round
CF PharmTech has raised $65M in a Series D financing with a future Industry Investment Fund, a private equity fund managed by SDIC Fund Management Corporation Limited, led the financing along with other prestigious healthcare investment groups in China.
August 28, 2017
FDA OK’s Taipei-based company’s submissing for Naldebain in U.S.
Lumosa Herapeutics said Monday that the FDA has confirmed its submission of the NDA of LT1001 Naldebain in the US. Naldebain IM injection has received market authorization and launched in Taiwan as the world’s first 7-day long-acting analgesic injection for moderate to severe post-operative pain.
August 27, 2017
Novartis’s new drug reduces cardiovascular risk
Novartis has revealed primary data from CANTOS, a Phase III study evaluating quarterly injections of ACZ885 (canakinumab) in people with a prior heart attack and inflammatory atherosclerosis as measured by high-sensitivity C-reactive protein (hsCRP) levels of >=2mg/L, a known marker of inflammation.